



# EBA RTS IMMV

Public hearing

15 December 2021

# Introduction



- The **proposal** included in the CP builds on:
  - The 2016 ESA joint RTS on risk mitigation techniques for OTC derivatives not cleared by a central counterparty (CCP) - adopted as DR (EU) 2016/2251 - which entered into force at the beginning of 2017
  - EMIR amendment (EMIR refit), which includes a specific mandate for EBA on the validation process and powers for CAs to validate IM models.
- Approval of IM models was not included in the ESA RTS on un-cleared derivatives due to a lack of a legal basis, which has since been included – in line with the recommendations of the ESAs.
- The RTS is however also mindful of the requirements set out in the original Basel/IOSCO framework, which requires model approval.

# Legal mandate



- The EBA, in cooperation with ESMA and EIOPA, has been mandated to develop draft regulatory technical standards (RTS) to **specify the supervisory procedures** that would **ensure initial and ongoing validation** of the risk-management procedures referred to in Article 11(15) of Regulation (EU) No 648/2012 (EMIR) on uncleared over-the-counter (OTC) derivatives.
- The RTS is restricted to approval of IM models, given that VM is based on MtM. This implies that the RTS solely deals with procedures for validating the IM model.
- This validation framework has been designed to operate with the requirements set out in the Delegated Regulation (EU) 2016/2251 on uncleared OTC derivatives.
- It also takes into consideration well-known internal market risk models approval practices, such as the ones laid down in the Delegated Regulation (EU) 2015/942 on model changes, and the final draft RTS on the assessment methodology for market risk internal models.
- Collaboration with ESMA and EIOPA in order to ensure consistency with other frameworks.

# Current situation on IM application

- Focus on:
  - **Number of subjects** (hundreds already in scope of IM, plus many others will follow)
  - **Variety of subjects** (international banks/OTC dealers vs final user – smaller banks, inv funds, insurances, pension funds, etc.)
  - Model already in place (phases already implemented)
- Industry suggestions on how to structure this project:
  - General grandfathering of the model in place
  - No approval for smaller subjects
  - Single validation authority
- These seem contrary to the legal mandate: validation must happen; no exemption for smaller institutions; no single authority to validate model
- The proposal included in the CP is pragmatic: **proportionate approach** (separating big and small institutions); **transitional phase** with no-objection approval; **facilitation for externalised models**.

## Proportionate approach

- The **great variety of subjects** in scope suggests that provisions should be differentiated based on type of subject and size of activity
- **Banks and banking groups above 750 bn €** of AANA OTC derivatives will follow the standardised process for validation; the rest will follow the simplified process
- Derogation: subjects above 50 bn € of AANA may be validated via the standardised process if the CAs deemed it necessary
- Derogation to the pre-validation principle: for smaller subjects only, CAs may allow the application of the model up to 1 year after submission of the notification of the validation request

## Standardised Process – Section 2 (Articles 4-23)

- General provisions, governance – robust model governance – complemented with clear quantitative requirements
- Requirements to submit documentation for **initial and on-going validation** – the latter in particular in case of material changes and extension
- Specification of material changes and extensions: +/- 5% & additional condition OR +/- 10% (without additional condition)
- Notification of non-material changes and extensions -> ex-ante notification OR ex-post notification once a year after implementation

## Standardised Process – Governance 1/3

- CA shall verify that the *“counterparty has a clear organisational structure for the **governance and management** of the model with well defined, transparent and appropriate lines of responsibility”*
- **Senior management** should be actively involved and ensure adequate resources; approves policy; takes corrective actions; follows recommendations; approves methodologies; is aware of overshootings; receives notifications of material changes or extensions
- Independence of **model implementation unit**; represented in decision-making process; adequate and proportionate; report to SR management; responsible for the outcome; produces a report on IM model
- **Audit** independence; adequate resources; adequate process in place to follow audit recommendations; audit review the model and prepare a report (annual basis) to SR management; CA shall assess that remediations of issues are relevant, material and credible; and where appropriate remediations actions are adopted and followed

## Standardised Process – Governance 2/3

- CA shall verify:
  - (a) **internal validation** not involved in development;
  - (b) adequate resources, experience and qualification;
  - (c) continuous monitoring (especially (i) overshooting and (ii) change or extension);
  - (d) findings of validation are reported in a validation report;
  - (e) the validation report is comprehensive and sound.
  
- CA shall verify internal validation of: (a) general structure; & (b) implementation of the model (appropriateness of model, assumption and calibration process, performance of the model – BT; accuracy of the implementation);
  
- possibility to outsource, subject to specific conditions (plans, reports and results are available to counterparty and adequate resources of the third-party).



## Standardised Process – Governance 3/3

- Internal validation of model calibration – Static backtesting (for every netting set above 50 mil €): at least at the end of every quarter, using the netting set and the IM computed at the end of that quarter: (i) identify MPoR; (ii) identify calibration period; (iii) – (v) compute a loss applying the returns identified in the calibration period; (vi) build a time series of the losses and count the overshootings.
- Used in the end-of-day valuation process; reflects only changes in **valuation adjustments** that are included in the counterpart's initial margin model and that are calculated **on a daily basis**; only for instruments covered by the model.
- Overshootings should be analysed, documented and communicated to CAs (**when > 10**).
- Each netting set is classified according to traffic light definition (green, amber, red) -> thresholds defined accordingly to Art 14.7 methodology.
- Differences with industry practice: BT time series is linked to calibration period, just IM is rolling; green and red thresholds are based on distribution X, based on proper empirical evidence – not necessarily Normal distribution

## Standardised Process – Quantitative assessment 1/2

- Dynamic backtesting (for every netting set above 50 mil): at least at the end of every quarter, computed at the end of that quarter: (i) identify last 250 days; (ii) compute the change in value of netting set (1 business day / for each 250 observations); (iii) compute the IM (1-day MPoR / for each 250 observations); (iv) compute a loss applying by comparing change in value & IM; (v) build a time series of the losses and counting the overshootings.
- Used in the end-of-day valuation process; reflects only changes in **valuation adjustments** that are included in the counterpart's initial margin model and that are calculated **on a daily basis**; only for instruments covered by the model.
- Overshootings should be analysed, documented and communicated to CAs (**when > 2**).
- Each netting set is classified according to **traffic light definition** (green, amber, red) - > thresholds defined accordingly to Art 17.7 methodology.
- Note: BT time series is fixed to 250 days, netting set composition and IM are rolling; green and red thresholds are based on distribution X, based on proper empirical evidence – not necessarily Normal distribution – requirements 17.2-3-4-8-9-10-11 are identical to 14.2-3-4-8-9-10-11

## Standardised Process – Quantitative assessment 2/2

- **Appropriateness of modelling assumptions:** well justified distributional and any other relevant statistical assumptions.
- Where the **risk factor** is incorporated into a counterparty's pricing model, but **not into** its initial margin **model** referred to in that Article, the counterparty provides an appropriate justification for such an omission.
- Capture of **non-linearities:** use of at least 1st and 2nd order Taylor series; assessment of time effect.
- **Use of proxies:** when market data are not sufficient or not reflecting true volatility of the position, conservativeness, periodic review of the proxies.
- Requirement to set up processes to identify **illiquid positions** and positions with limited price transparency and to capture their risks in the initial margin model conservatively.
- Assess the use of **empirical correlations**.

## Simplified Process – Section 3 (Articles 24-29)

- Same structure as for the standardised process (general provisions, governance, quantitative assessment), but...
- **Thresholds are x2** (i.e., 10% and 20%) for defining material changes and extensions; but for non-material changes, ex-post notification applies, once a year.
- Reduced set of documentation requirements + self-assessment of the compliance with requirements.
- Governance: **less granular** documentation requirements:
  - (a) organisation structure of SR management; (b) documented evidence of SR management understanding of the model
  - (a) organisation structure of implementing unit/audit/internal validation; (b) evidence of independence; (c) reports produced.
- Backtesting requirements: **simple dynamic BT** (as STD process), but no other requirements.

## Transitional phase (Article 30)

- 2 years starting from the application of the rules (which is phased-in).
- Only for CNTPs applying the model before the application of the rules, that submit the request of validation to their CAs.
- CAs can validate the model by non-objecting to its use (two years to raise issues with CNTPs). This “non-objection” approval is valid only during the transition phase.
- The standard rule is ex-ante validation (once transition ends).

## Phase-in implementation (Article 31)

- Section 2 -> **1-year** delay
- Section 3 -> **2 or 3-year** delay, depending on the size of the AANA (50 bn threshold)

## Provision for outsourced IM model

- Outsourcing: *“Where a counterparty has delegated some or all tasks, activities or functions related to the design, calibration, implementation, internal validation and audit of its initial margin model to a third party, or has purchased an initial margin model or services related to an initial margin model from a third party, competent authorities shall verify that the delegation or purchase does not hinder the application of the assessment methodology referred to in this Regulation and, more in particular”*: (a) awareness of the senior management; (b) knowledge of the staff; (c) continuity; (d) non-limitation in the function outsourced; (e) full access to information for CA.
  
- Use of Validation results: *“For the purposes of verifying compliance of the general structure of the model with the governance requirements referred to in Article 13”, use of own results and findings (or the ones of a CAs in the scope of this Regulation), where: (a) design and calibration outsourced to the same subject & (b) same structure and calibration + (c) avails evidence of validation by CAs & (d) avails evidence of internal validation.*

## Next steps

- Consultation period ends on 4 Feb 2022
  - Comments to be received before
  
- Based on the comments received, EBA will review the responses and plans to finalise, most likely, by Q3 2022
  
- Focus will be, as highlighted today, at ensuring a gradual transition to approving models
  - Awareness of both limits to supervisory and counterparty resources





## EUROPEAN BANKING AUTHORITY

Tour Europlaza, 20 avenue André Prothin, CS 30154  
92927 Paris La Défense CEDEX, FRANCE

---

Tel: +33 1 86 52 70 00

E-mail: [info@eba.europa.eu](mailto:info@eba.europa.eu)

---

<https://eba.europa.eu/>